HTA guidance from NICE, the SMC and the AWMSG

Combined hormonal contraception—update (Faculty of Sexual & Reproductive Healthcare)

September 2018: Independent professional body guideline

Asthma (update)

September 2018: NICE Quality Standard

Depression in adults (update)

September 2018: NICE Quality Standard

Eating disorders

September 2018: NICE Quality Standard

Ovarian cancer (refresh)

September 2018: SIGN guidance

Renal replacement therapy

October 2018: NICE Clinical Guideline

Decision making and mental capacity

October 2018: NICE Social Care Guidance

Foetal alcohol spectrum disorder (update)

October 2018: SIGN guidance

Abdominal aortic aneurysm: diagnosis and management

November 2018: NICE Clinical Guideline

Contraceptive choices for women who are obese/overweight

November 2018: Independent professional body guideline

Visit the Guidelines website

After discount row, NICE finally says yes to first line Revlimid

17 May 2019
In a second piece of final draft guidance published today, NICE has also recommended Revlimid as a second line therapy with dexamethasone. ... The new decision by NICE now means that those patients have an effective alternative.”.

Akcea steals march on Alnylam with NICE approval

16 Apr 2019
Advantage to Tegsedi over Onpattro. NICE has recommended Akcea Therapeutics’ rare disease treatment Tegsedi (inotersen), after the company improved its price offer. ... NICE’s ruling adds to the good news for Akcea, which in March gained a CHMP

NICE says no to Novartis’ Kisqali combo in breast cancer

11 Apr 2019
Double blow after Lilly rival recommended. Novartis’ hopes of a boost for under-performing breast cancer drug Kisqali have been hit by a negative verdict from NICE. ... by NICE alongside fulvestrant for this patient group last week, albeit via the

NICE nod for Lilly’s breast cancer drug Verzenio via CDF

2 Apr 2019
In this case, NICE is waiting on the final analysis of the MONARCH 2 study is available, which is expected to be available in February 2020. ... NICE notes in its guidance that Verzenio and fulvestrant will be an option “where exemestane plus

NICE recommends MSD’s diabetes drug Steglatro

28 Mar 2019
In the UK, the treatment is priced at £29.40 for 28 days, a price which NICE points out is the lowest acquisition cost of any SGLT-2 inhibitor. ... The decision by NICE shows MSD’s commitment to meeting the needs of a growing population of people with

More news from PMLiVE on NICE, the SMC and the AWMSG